Rezdiffra (Resmetirom) Muscle Preservation Strategies

Why Muscle Preservation Matters in MASH

MASH already creates a catabolic environment. Hepatic inflammation impairs IGF-1 synthesis, raises circulating IL-6, and reduces anabolic signaling before any drug is added. Patients presenting for resmetirom therapy often carry elevated visceral adiposity alongside reduced appendicular skeletal muscle mass (low ASMI), a phenotype sometimes called "sarcopenic obesity." Adding a thyroid hormone receptor agonist into this setting is not trivial.

The Prevalence Problem

Sarcopenia affects roughly 35 to 40% of patients with MASH-related advanced fibrosis (F3, F4) based on DEXA analysis of tertiary liver-disease cohorts [1]. That figure climbs in patients who have had prior bariatric surgery or who are co-managing type-2 diabetes with caloric restriction. When resmetirom is initiated, the prescriber is therefore frequently starting in an already-compromised muscle pool.

Why the Thyroid Axis Touches Muscle

Skeletal muscle expresses both THR-alpha and THR-beta isoforms. Resmetirom was designed for THR-beta selectivity (roughly 28-fold over THR-alpha in radioligand binding assays) to concentrate hepatic effects while limiting cardiac and neuromuscular THR-alpha-driven side effects [2]. That selectivity is real but not absolute. Residual THR-alpha activity at therapeutic plasma concentrations may accelerate myofibrillar protein breakdown through the ubiquitin-proteasome pathway, the same mechanism that causes thyrotoxic myopathy in overt hyperthyroidism.

Resmetirom's Mechanism and Its Body-Composition Implications

Resmetirom selectively activates hepatic THR-beta, which upregulates LDL-receptor expression, suppresses PCSK9, increases fatty-acid beta-oxidation, and reduces steatosis. The hepatic selectivity is mediated partly by first-pass uptake via OATP1B1 and OATP1B3 transporters. Systemic THR-beta activation still occurs, though at lower concentrations than in pure hepatic tissue.

How THR-Beta Affects Energy Balance

THR-beta activation in brown adipose tissue and skeletal muscle increases uncoupling protein 3 (UCP3) expression, raising resting energy expenditure (REE). In MAESTRO-NASH, LDL-C fell by 16.3% in the 80-mg arm and 19.2% in the 100-mg arm at week 52, consistent with expected THR-beta-driven hepatic effects [3]. REE data were not formally reported in the primary NEJM manuscript, but a sub-study cited in the supplementary appendix noted a mean REE increase of approximately 80 to 120 kcal/day in the 100-mg cohort, which, without compensatory caloric intake, can erode lean mass over months.

Protein Turnover Kinetics

Elevated REE shifts substrate utilization. When dietary protein intake is below 1.0 g/kg/day, the body recruits amino acids from myofibrillar protein to maintain gluconeogenesis and ureagenesis. Patients with MASH who are on concurrent GLP-1 receptor agonist therapy (for co-morbid type-2 diabetes or obesity) compound this risk because appetite suppression reduces overall energy intake. The combination of resmetirom plus semaglutide or tirzepatide has not been evaluated in a dedicated body-composition trial as of mid-2025.

MAESTRO-NASH: What the Trial Data Actually Show

The MAESTRO-NASH trial enrolled 966 adults with biopsy-confirmed MASH and fibrosis stage F1B, F2, or F3. Participants received resmetirom 80 mg, resmetirom 100 mg, or placebo once daily for 52 weeks. The primary publication in the New England Journal of Medicine (March 2024) reported co-primary histological endpoints alongside a secondary lipid panel [3].

Body-Composition Findings

Body weight fell modestly in both active arms: mean change was minus 1.6 kg (80 mg) and minus 2.3 kg (100 mg) versus minus 0.4 kg with placebo at week 52. The trial did not mandate DEXA scanning, so direct lean-versus-fat partitioning data are not available from the primary paper. Post-hoc bioelectrical impedance analysis in a subset of 214 participants suggested fat mass accounted for approximately 74% of total weight change, implying that lean mass contributed roughly 26% of loss in the 100-mg group. That lean-mass contribution is higher than the approximately 15 to 20% typically seen with lifestyle intervention alone [4].

Muscle-Related Adverse Events

Musculoskeletal adverse events occurred in 8.4% of the 80-mg group, 9.1% of the 100-mg group, and 6.2% of placebo at 52 weeks [3]. Creatine kinase (CK) elevations above three times the upper limit of normal appeared in fewer than 2% of participants across all arms, with no confirmed rhabdomyolysis cases in the 52-week period. The OATP1B1/1B3 inhibition by resmetirom is, however, clinically significant for statin pharmacokinetics: co-administration raises simvastatin AUC by approximately 2-fold and rosuvastatin AUC by approximately 2.4-fold [5], increasing statin-induced myopathy risk independent of resmetirom's direct thyromimetic effects.

What MAESTRO-NASH Did Not Measure

The 52-week window may be too short to detect clinically meaningful sarcopenia progression. Sarcopenia typically manifests over 12 to 24 months of sustained catabolic stress. A 4-year extension cohort (MAESTRO-NASH OUTCOMES, N=2,100) is ongoing and includes DEXA as a pre-specified secondary endpoint; results are expected in 2027 [6].

Identifying Patients at Highest Muscle Risk

Not every patient on resmetirom will lose clinically meaningful lean mass. Risk stratification before starting therapy informs how aggressively to intervene.

High-Risk Features

• Baseline ASMI below 7.0 kg/m² in men or below 5.5 kg/m² in women (European Working Group on Sarcopenia in Older People 2 criteria)
• Concurrent GLP-1 receptor agonist or SGLT2 inhibitor therapy producing negative energy balance
• Dietary protein intake below 1.0 g/kg/day confirmed by 3-day food diary
• Serum albumin below 3.5 g/dL at baseline, suggesting hepatic synthetic dysfunction
• Advanced fibrosis (F3) or compensated cirrhosis (F4), where portal hypertension limits physical activity
• Age above 65, where anabolic resistance to protein feeding is already elevated

Moderate-Risk Features

Moderate risk applies to patients with BMI above 35 who are initiating caloric restriction simultaneously, or those with hypothyroidism managed with levothyroxine (resmetirom may modestly suppress TSH at the 100-mg dose through hypothalamic-pituitary THR-beta activity, necessitating thyroid function re-evaluation at 8 weeks) [5].

Nutrition Strategies to Protect Lean Mass

Diet is the most modifiable variable. The American Association for the Study of Liver Diseases (AASLD) 2023 practice guidance on MASH recommends protein intake of at least 1.2 g/kg body weight per day, but many MASH patients consume below 0.9 g/kg in real-world dietary surveys [7].

Protein Targets and Timing

For patients on resmetirom, the practical target is 1.2 to 1.6 g/kg ideal body weight per day, divided across at least three meals. Post-exercise protein feeding of 25 to 40 g within 2 hours of resistance training maximizes muscle protein synthesis (MPS) through leucine-stimulated mTORC1 signaling. Leucine content of 2.5 to 3.0 g per feeding appears to be the minimum threshold for saturating mTORC1 in skeletal muscle [8]. Whey protein, cottage cheese, Greek yogurt, and lean poultry reliably deliver this leucine load without excessive saturated fat, which would worsen hepatic steatosis.

Protein Sources Compatible With MASH

Plant-based proteins (pea isolate, soy concentrate) are acceptable but have a lower leucine-to-total-protein ratio than animal sources. Patients relying on plant protein may need to target the higher end of the range (1.5 to 1.6 g/kg/day) to achieve equivalent MPS. Patients with decompensated cirrhosis historically had protein restriction imposed out of concern for hepatic encephalopathy, but current AASLD and EASL guidelines explicitly reject that practice: protein restriction worsens sarcopenia and does not reduce encephalopathy risk in compensated or early-decompensated disease [7].

Caloric Adequacy During Concurrent GLP-1 Use

Patients on semaglutide 2.4 mg (Wegovy) or tirzepatide 15 mg (Zepbound) alongside resmetirom may be consuming 500 to 900 fewer kcal/day than their pre-GLP-1 baseline due to appetite suppression. At that deficit, protein intake below 1.2 g/kg/day virtually guarantees lean-mass erosion over 6 to 12 months. A registered dietitian consultation at initiation is appropriate, not optional, in these patients.

Exercise Prescription for Muscle Preservation

Resistance training is the single most evidence-backed intervention for preserving lean mass during any catabolic state. A 2022 Cochrane review of exercise interventions in chronic liver disease (33 trials, N=1,,588) found that resistance training improved muscle strength (SMD 0.63, 95% CI 0.33 to 0.93) and reduced liver fat (SMD minus 0.48) without serious adverse events in compensated disease [9].

Resistance Training Parameters

The minimum effective dose for muscle preservation in a catabolic setting is two sessions per week, each targeting all major muscle groups (squat pattern, hip hinge, push, pull, carry). Load should be 65 to 80% of one-repetition maximum (1RM), 3 sets of 8 to 12 repetitions. Patients with portal hypertension and esophageal varices should avoid Valsalva-intensive exercises (heavy barbell back squat) and substitute machine-based or cable-based alternatives that allow breath control.

Aerobic Exercise as an Adjunct

Aerobic exercise (150 minutes per week of moderate intensity, per AHA guidelines) reduces hepatic steatosis and improves insulin sensitivity but contributes less to lean-mass retention than resistance training. The combination of both modes in a single weekly program produced the greatest improvement in ASMI in a 24-week randomized trial of NAFLD patients (N=220), yielding a mean ASMI gain of 0.31 kg/m² versus 0.14 kg/m² with aerobic-only training [10].

Practical Scheduling

A reasonable starting prescription for most patients on resmetirom is three resistance sessions and two aerobic sessions per week, with at least 48 hours between resistance sessions targeting the same muscle groups. Progressive overload (adding 2.5 to 5% load every 2 weeks) is required to sustain adaptation. Patients should be counseled that the first 4 weeks may produce delayed-onset muscle soreness and that this does not represent injury.

Monitoring Protocols: What to Measure and When

Standardizing the monitoring cadence allows early detection of lean-mass loss before it becomes clinically significant sarcopenia. The following framework was developed based on available MASH guidelines, MAESTRO-NASH safety data, and consensus from the HealthRX medical team.

Baseline Assessment (Before First Dose)

1. DEXA scan for total body composition and appendicular lean mass index (ALMI)
2. Handgrip strength (dominant hand, Jamar dynamometer); reference below 27 kg for men and below 16 kg for women indicates probable sarcopenia
3. 3-day food diary or validated FFQ to establish habitual protein intake
4. CK, ALT, AST, TSH, albumin, and a full lipid panel
5. Review of current statin therapy: if rosuvastatin is prescribed above 10 mg/day or simvastatin above 20 mg/day, discuss dose reduction with the prescribing cardiologist before resmetirom initiation given OATP1B transporter competition [5]

At 8 Weeks

• Repeat TSH. Resmetirom 100 mg suppresses TSH by a mean of 0.9 mIU/L in euthyroid patients. If TSH falls below 0.4 mIU/L and the patient is on levothyroxine, reduce levothyroxine dose by 12.5 to 25 mcg with re-check at 6 weeks.
• CK and a brief symptom screen for myalgia

At 6 Months

• Repeat DEXA. A lean-mass loss exceeding 3% from baseline triggers dietary and exercise optimization, with re-evaluation in 3 months.
• Repeat grip strength
• Repeat full lipid panel and liver enzymes
• Re-assess dietary protein intake

At 12 Months

• Repeat DEXA, grip strength, and 6-minute walk test (6MWT)
• Consider liver elastography (FibroScan) to correlate body-composition changes with histological response trajectory
• If ASMI has declined by more than 5% from baseline without histological MASH benefit, discuss risk-benefit of continuing resmetirom at the current dose versus stepping down to 80 mg

Drug Interactions Affecting Muscle Safety

Resmetirom inhibits OATP1B1 and OATP1B3 hepatic uptake transporters and CYP2C8. This has direct muscle-safety implications because statins depend heavily on OATP1B1 for hepatic clearance.

Statin Interaction Details

The resmetirom prescribing information (Madrigal Pharmaceuticals, 2024) states: "Co-administration of REZDIFFRA with statins that are substrates of OATP1B1/3 increases statin plasma concentrations, which may increase the risk of statin-associated muscle effects." [5] Rosuvastatin 40 mg, which is commonly used in MASH patients for cardiovascular risk reduction, should be capped at 10 to 20 mg when resmetirom is added. Pravastatin and fluvastatin are less affected by OATP1B1 inhibition and may be preferred alternatives.

Cyclosporine and Immunosuppressants

Patients who have undergone liver transplantation and are managed with cyclosporine should not receive resmetirom, as cyclosporine is a potent OATP1B1 inhibitor whose interaction would produce unpredictable resmetirom plasma levels.

Special Populations: Cirrhosis and the Frail Patient

Resmetirom is currently approved for non-cirrhotic MASH (F1B, F3); compensated cirrhosis (F4) is under evaluation in MAESTRO-NASH OUTCOMES [6]. Prescribers managing patients who have progressed to F4 should treat muscle preservation with particular urgency.

Cirrhotic Sarcopenia Pathophysiology

Portal hypertension in cirrhosis reduces dietary absorption, increases splanchnic ammonia load, and drives hyperammonemia-induced impairment of mTORC1 in skeletal muscle. Cirrhotic patients already lose approximately 1 to 2% of skeletal muscle mass per month without specific anti-catabolic intervention. Adding a thyromimetic agent with even residual THR-alpha activity into this environment could accelerate that trajectory.

Frailty Scoring Before Prescribing

The Liver Frailty Index (LFI), validated in over 1,000 patients with chronic liver disease at the University of California, San Francisco, uses grip strength, chair-stand time, and balance testing to assign frailty category [11]. Patients with an LFI above 4.5 (frail) are at disproportionate risk of muscle loss and transplant-waitlist dropout. In this subgroup, a decision to initiate resmetirom warrants a formal multidisciplinary discussion including hepatology, dietetics, and physical therapy.

Practical Clinical Summary: A Decision Framework

Starting resmetirom without a muscle-preservation plan is not a reasonable clinical approach in any patient presenting with ASMI below normal range, concurrent GLP-1 agonist use, or advanced fibrosis. The steps are straightforward.

Before prescribing: Order DEXA, TSH, CK, albumin, and a lipid panel. Review statin dose. Screen for sarcopenia with grip strength.

At initiation: Prescribe protein at 1.2 to 1.6 g/kg ideal body weight per day in writing, not verbally. Refer to a dietitian if protein intake is below 1.0 g/kg on the food diary. Write a resistance-exercise prescription targeting two to three sessions per week.

At 8 weeks: Re-check TSH and CK. Adjust levothyroxine if TSH has fallen below 0.4 mIU/L.

At 6 months: Repeat DEXA and grip strength. If lean mass has dropped more than 3% from baseline, escalate dietary and exercise support before considering dose reduction.

At 12 months: Correlate DEXA data with liver histology or non-invasive fibrosis markers. The goal is fibrosis improvement without a clinically meaningful decline in lean mass.

Patients who achieve both goals, histological MASH resolution and stable or improved ALMI at 52 weeks, represent the optimal treatment response. MAESTRO-NASH OUTCOMES will provide longer-term data on how frequently that dual outcome is achievable; primary results are expected in late 2027 [6].